A trial of GSK2256098 and trametinib for advanced cancers

This trial is looking at a new drug called GSK2256098 alongside trametinib for solid tumours that are not responding to other treatments. A solid tumour is any cancer except lymphoma, leukaemia and myeloma.

Trametinib is a type of biological therapy called a MEK inhibitor. MEK is a body protein that sends signals to cells telling them to divide and grow. Blocking MEK may also stop cancer cells growing.

GSK2256098 is another biological therapy called a FAK inhibitor. FAK is a protein that plays a role in the way cancer grows and spreads. Blocking it may stop cancer spreading.

There are 2 parts to this trial. In the 1st part the researchers want to find out the best dose of each drug to give together.

In the 2nd part the researchers will use the best dose of each drug to find out how well this combination of drugs works for people with mesothelioma of the lung.

The main aims of the trial are to find out

• What are the best doses of GSK2256098 and trametinib to give together

• The side effects of giving these drugs together

• More about what happens to GSK2256098 and trametinib in the body

• How well GSK2256098 alongside trametinib works for people with mesothelioma of the lung